None reported.

Prophylactic to reduce incidence of ifofamide-induced haemorrhage.

G.I.effect, headache, malaise, skin rash. False positive results in diagnostic tests for urine ketones. I.V.administration: Tachycardia and transient hypertension. Oral: Unpleasant taste,yellowing of teeth on prolonged use. Inhalation: Cough,bronchospasm and retrosternal burning.

Pregnancy. Special precautions: False results of tests for ketone bodies in urine, lactation.

Indications:

Prophylactic to reduce incidence of ifofamide-induced haemorrhage.

Dosage:

Given as IV bolus in a dosage equal to 20% of ifosfamide .dosage(w/w) at the time of ifosfamide administration and 4 and 8 hours after each dose of ifosfamide. Total daily dose of mesna is 60% of the ifosfamide dose.

Pharmacology:

Mesna injection is a detoxifying agent to inhibit the haemorrhagic cystitis induced by ifosfamide . In the kidney, the mesna is reduced to the free thiol compound, mesna, which reacts chemically with the urotoxic ifosfamide metabolite.

Pharmacokinetics:

At doses of 2 to 4g its terminal elimination half-life is about 7 hours

Not applicable

Pregnancy:

Mesna should be given to pregnant women only if the potential benefits outweighs the potential risks.

Lactation:

Not known whether mesna is excreted into the breast milk. Because of potential risks, decide whether to discontinue nursing or to discontinue the drug, depending on the importance of the drug to the mother.